Solid Biosciences Inc. (SLDB)
SLDB Stock Price Chart
Explore Solid Biosciences Inc. interactive price chart. Choose custom timeframes to analyze SLDB price movements and trends.
SLDB Company Profile
Discover essential business fundamentals and corporate details for Solid Biosciences Inc. (SLDB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jan 2018
Employees
100.00
Website
https://www.solidbio.comCEO
Alexander G. Cumbo
Description
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
SLDB Financial Timeline
Browse a chronological timeline of Solid Biosciences Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.43.
Earnings released on 12 May 2026
EPS came in at -$0.52 falling short of the estimated -$0.40 by -30.00%.
Earnings released on 19 Mar 2026
EPS came in at -$0.50 surpassing the estimated -$0.51 by +1.96%.
Earnings released on 3 Nov 2025
EPS came in at -$0.48 falling short of the estimated -$0.42 by -14.29%.
Earnings released on 12 Aug 2025
EPS came in at -$0.42 surpassing the estimated -$0.51 by +17.65%.
Earnings released on 15 May 2025
EPS came in at -$0.59 falling short of the estimated -$0.53 by -11.32%.
Earnings released on 6 Mar 2025
EPS came in at -$0.89 falling short of the estimated -$0.79 by -12.66%.
Earnings released on 6 Nov 2024
EPS came in at -$0.79 falling short of the estimated -$0.67 by -17.91%.
Earnings released on 13 Aug 2024
EPS came in at -$0.61 surpassing the estimated -$0.68 by +10.29%.
Earnings released on 15 May 2024
EPS came in at -$0.64 falling short of the estimated -$0.57 by -12.28%.
Earnings released on 13 Mar 2024
EPS came in at -$1.00 surpassing the estimated -$1.01 by +0.99%, while revenue for the quarter reached $4.74m .
Earnings released on 8 Nov 2023
EPS came in at -$1.05 surpassing the estimated -$1.20 by +12.50%.
Earnings released on 14 Aug 2023
EPS came in at -$1.25 surpassing the estimated -$1.52 by +17.76%.
Earnings released on 11 May 2023
EPS came in at -$1.54 surpassing the estimated -$1.83 by +15.85%.
Earnings released on 23 Mar 2023
EPS came in at -$0.68 surpassing the estimated -$2.70 by +74.81%, while revenue for the quarter reached $8.09m , beating expectations by +591.79%.
Earnings released on 10 Nov 2022
EPS came in at -$2.71 falling short of the estimated -$2.59 by -4.63%.
Stock split effective on 28 Oct 2022
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 Aug 2022
EPS came in at -$3.30 falling short of the estimated -$3.15 by -4.76%, while revenue for the quarter reached $6.17m , beating expectations by +51.03%.
Earnings released on 27 Apr 2022
EPS came in at -$3.30 falling short of the estimated -$2.70 by -22.22%, while revenue for the quarter reached $1.93m , missing expectations by -28.12%.
Earnings released on 14 Mar 2022
EPS came in at -$2.55 surpassing the estimated -$3.00 by +15.00%, while revenue for the quarter reached $3.15m , beating expectations by +82.08%.
Earnings released on 3 Nov 2021
EPS came in at -$2.40 surpassing the estimated -$2.85 by +15.79%, while revenue for the quarter reached $3.54m , beating expectations by +167.95%.
Earnings released on 16 Aug 2021
EPS came in at -$2.55 surpassing the estimated -$2.70 by +5.56%, while revenue for the quarter reached $3.59m , beating expectations by +172.27%.
SLDB Stock Performance
Access detailed SLDB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
